{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:17Z","timestamp":1786980197299,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["JYZZ073"],"award-info":[{"award-number":["JYZZ073"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00432-022-04090-2","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T06:02:20Z","timestamp":1662876140000},"page":"2293-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-5216","authenticated-orcid":false,"given":"Yunteng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,11]]},"reference":[{"key":"4090_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1368-8375(99)00085-8","volume":"36","author":"MJ Hicks","year":"2000","unstructured":"Hicks MJ, Flaitz CM (2000) Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol 36:152\u2013169","journal-title":"Oral Oncol"},{"key":"4090_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1368-8375(99)00017-2","volume":"35","author":"CM Lopez-Graniel","year":"1999","unstructured":"Lopez-Graniel CM, Ochoa-Carrillo FJ, Meneses-Garcia A (1999) Malignant melanoma of the oral cavity: diagnosis and treatment experience in a Mexican population. Oral Oncol 35:425\u2013430","journal-title":"Oral Oncol"},{"key":"4090_CR3","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1111\/ajd.12603","volume":"58","author":"SI Yamada","year":"2017","unstructured":"Yamada SI, Kurita H, Kamata T et al (2017) Clinical investigation of 38 cases of oral mucosal melanoma: a multicentre retrospective analysis in Japan. Australas J Dermatol 58:e223\u2013e227","journal-title":"Australas J Dermatol"},{"key":"4090_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/CAD.0000000000000454","volume":"28","author":"F Perri","year":"2017","unstructured":"Perri F, Pisconti S, Favia M et al (2017) Optimal multidisciplinary treatment of oral cavity mucosal melanoma: outcome analysis in a case series. Anticancer Drugs 28:327\u2013334","journal-title":"Anticancer Drugs"},{"key":"4090_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0030-4220(94)90121-X","volume":"78","author":"N Tanaka","year":"1994","unstructured":"Tanaka N, Amagasa T, Iwaki H et al (1994) Oral malignant melanoma in Japan. Oral Surg Oral Med Oral Pathol 78:81\u201390","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"4090_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.oraloncology.2014.01.008","volume":"50","author":"Y Wu","year":"2014","unstructured":"Wu Y, Zhong Y, Li C et al (2014) Neck dissection for oral mucosal melanoma: caution of nodular lesion. Oral Oncol 50:319\u2013324","journal-title":"Oral Oncol"},{"key":"4090_CR7","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.7150\/jca.20935","volume":"8","author":"X Ma","year":"2017","unstructured":"Ma X, Wu Y, Zhang T et al (2017) Ki67 Proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. J Cancer 8:3828\u20133837","journal-title":"J Cancer"},{"key":"4090_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.oraloncology.2018.10.022","volume":"87","author":"Y Wu","year":"2018","unstructured":"Wu Y, Wang L, Ma X et al (2018) The existence of early stage oral mucosal melanoma: a 10-year retrospective analysis of 170 patients in a single institute. Oral Oncol 87:70\u201376","journal-title":"Oral Oncol"},{"key":"4090_CR9","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","volume":"19","author":"B Lian","year":"2013","unstructured":"Lian B, Si L, Cui C et al (2013) Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 19:4488\u20134498","journal-title":"Clin Cancer Res"},{"key":"4090_CR10","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng X, Yan X, Chi Z et al (2019) Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol 37:2987\u20132999","journal-title":"J Clin Oncol"},{"key":"4090_CR11","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00432-021-03562-1","volume":"147","author":"L Susok","year":"2021","unstructured":"Susok L, Stucker M, Bechara FG et al (2021) Multivariate analysis of prognostic factors in patients with nodular melanoma. J Cancer Res Clin Oncol 147:2759\u20132764","journal-title":"J Cancer Res Clin Oncol"},{"key":"4090_CR12","doi-asserted-by":"crossref","unstructured":"Robsahm TE, Helsing P, Svendsen HL, et al (2021) Clinical suspicion sensitivity of nodular and superficial spreading melanoma. Acta Derm Venereol 101:adv00427","DOI":"10.2340\/00015555-3782"},{"key":"4090_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaad.2020.11.047","volume":"84","author":"BS Allais","year":"2021","unstructured":"Allais BS, Beatson M, Wang H et al (2021) Five-year survival in patients with nodular and superficial spreading melanomas in the US population. J Am Acad Dermatol 84:1015\u20131022","journal-title":"J Am Acad Dermatol"},{"key":"4090_CR14","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472\u2013492","DOI":"10.3322\/caac.21409"},{"key":"4090_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12967-019-2106-x","volume":"17","author":"L Xu","year":"2019","unstructured":"Xu L, Cheng Z, Cui C et al (2019) Correction to: frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy. J Transl Med 17:358","journal-title":"J Transl Med"},{"key":"4090_CR16","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-018-6503-9","volume":"25","author":"C Cui","year":"2018","unstructured":"Cui C, Lian B, Zhou L et al (2018) Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients. Ann Surg Oncol 25:2184\u20132192","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"4090_CR17","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0959-8049(98)00002-1","volume":"34","author":"BE Hillner","year":"1998","unstructured":"Hillner BE (1998) Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer 34(Suppl 3):S18-21","journal-title":"Eur J Cancer"},{"key":"4090_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood JM, Strawderman MH, Ernstoff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7\u201317","journal-title":"J Clin Oncol"},{"key":"4090_CR19","doi-asserted-by":"publisher","first-page":"11944","DOI":"10.4238\/2015.October.5.8","volume":"14","author":"R Wang","year":"2015","unstructured":"Wang R, Jing G, Lv J et al (2015) Interferon-alpha-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma. Genet Mol Res 14:11944\u201311954","journal-title":"Genet Mol Res"},{"key":"4090_CR20","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","volume":"32","author":"LE Flaherty","year":"2014","unstructured":"Flaherty LE, Othus M, Atkins MB et al (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma\u2013an intergroup study of cancer and leukemia Group B, Children\u2019s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol 32:3771\u20133778","journal-title":"J Clin Oncol"},{"key":"4090_CR21","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","volume":"19","author":"JM Kirkwood","year":"2001","unstructured":"Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801. J Clin Oncol 19:2370\u20132380","journal-title":"J Clin Oncol"},{"key":"4090_CR22","first-page":"1186","volume":"19","author":"P Koelblinger","year":"2021","unstructured":"Koelblinger P, Hoellwerth M, Dernoscheg MT et al (2021) Adjuvant anti-PD-1 antibody treatment in stage III\/IV melanoma: real-world experience and health economic considerations. J Dtsch Dermatol Ges 19:1186\u20131198","journal-title":"J Dtsch Dermatol Ges"},{"key":"4090_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","volume":"12","author":"B Tang","year":"2019","unstructured":"Tang B, Yan X, Sheng X et al (2019) Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol 12:7","journal-title":"J Hematol Oncol"},{"key":"4090_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144","journal-title":"N Engl J Med"},{"key":"4090_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/cam4.732","volume":"5","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Green MR et al (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5:1481\u20131491","journal-title":"Cancer Med"},{"key":"4090_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14740338.2016.1248402","volume":"16","author":"E Ramelyte","year":"2017","unstructured":"Ramelyte E, Schindler SA, Dummer R (2017) The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opin Drug Saf 16:41\u201353","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04090-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04090-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04090-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T06:09:37Z","timestamp":1682402977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04090-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4090"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04090-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,11]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Because of the retrospective nature of this study, consent was not obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}